mWACh-PrEP: A SMS-based Support Intervention to Enhance PrEP Adherence During Pregnancy and Breastfeeding

Launched by UNIVERSITY OF WASHINGTON · Jul 14, 2020

Keywords

ClinConnect Summary

The mWACh-PrEP trial is studying a new way to help pregnant women stay on a medication called PrEP, which helps prevent HIV. This trial focuses on women who are at high risk of HIV during pregnancy and breastfeeding. Researchers will use a text messaging program to send helpful reminders and support to women who have started taking PrEP during their routine antenatal care visits. The goal is to see if this SMS support can increase the number of women who continue taking PrEP for at least six months after giving birth, compared to standard in-person counseling.

To be eligible for this trial, women must be at least 18 years old, pregnant between 24 to 32 weeks, HIV negative, and plan to stay in the area for at least a year after giving birth. They also need to have a high risk score for HIV and should already be taking PrEP. Participants will receive regular text messages and may be asked to share their experiences through interviews or focus groups. This trial aims to find out if the text messaging support is helpful and cost-effective, ultimately improving care for women at risk of HIV during and after pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Pregnant women presenting for routine antenatal care (ANC) who are:
• • ≥18 years old
• • 24-32 weeks gestation
• • No documented tuberculosis infection
• • HIV negative (based on ANC HIV testing)
• • Plan to reside in area for at least one year postpartum
• • Plan to receive antenatal, postnatal, and infant care at study facility
• • Initiated PrEP during routine ANC
• • Have an HIV risk score \>6 (based on Pintye et al 2017).
• Exclusion Criteria:
• • Do not plan to remain in the study site catchment area for at least 1 year
• • Do not have mobile phones.